Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Renzapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 7/20 | 1.00 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 3/20 | 1.00 |
| ▸ | HTR3B known ✓ | O95264 | 3/20 | 1.00 |
| ▸ | HTR3D known ✓ | Q70Z44 | 3/20 | 1.00 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Renzapride SCHEMBL4534994 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL678616 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5371909 | 0.99 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5765864 | 0.99 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5367707 | 0.99 | HTR3A (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5767174 | 0.98 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL5371617 | 0.98 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL1650356 | 0.98 | HTR3A (0.96) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL8292934 | 0.89 | HTR3A (0.80) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Renzapride SCHEMBL1047947 | 0.88 | HTR3A (0.78) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1730 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | claimed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | claimed |
| US-20240324947-A1 | ENERGY WAVE REFRACTION AND METHODOLOGY TO DETECT GASTRIC DISTENTION AND PREVENT ASPIRATION | BAYLOR COLLEGE OF MEDICINE (US) | 2024-10-03 | — | — | US | claimed |
| CN-116211847-B | Application of saururus chinensis ketone in preparation of medicine for preventing and/or treating irritable bowel syndrome | 四川省医学科学院·四川省人民医院 | 2024-09-13 | — | — | CN | claimed |
| EP-4373398-A1 | ENERGY WAVE REFRACTION AND METHODOLOGY TO DETECT GASTRIC DISTENTION AND PREVENT ASPIRATION | Baylor College of Medicine (US) | 2024-05-29 | — | — | EP | claimed |
| CN-117897088-A | Method for energy wave refraction, detecting gastric distention and preventing aspiration | 贝勒医学院 | 2024-04-16 | — | — | CN | claimed |
| WO-2024005132-A1 | PHARMACEUTICAL COMPOSITION | マルホ株式会社 | 2024-01-04 | — | — | WO | claimed |
| CN-116211847-A | Application of saururus chinensis ketone in preparation of medicine for preventing and/or treating irritable bowel syndrome | 四川省医学科学院·四川省人民医院 | 2023-06-06 | — | — | CN | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2001095903-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2001062257-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC. (US) | 2001-08-30 | — | — | WO | claimed |
| EP-1107746-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS | Sepracor Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| WO-2000064441-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-11-02 | — | — | WO | claimed |
| WO-2000051546-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC. (US) | 2000-09-08 | — | — | WO | claimed |
| WO-2000010551-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2000-03-02 | — | — | WO | claimed |
| EP-0617620-A1 | USE OF 5-HT4 MODULATORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF THE BLADDER DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1994-10-05 | — | — | EP | claimed |
| WO-1993012785-A1 | USE OF 5-HT4 MODULATORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF THE BLADDER DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1993-07-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | HTR4, IL4, FFAR4 | HTR3A 14/4885HTR3E 29/4885HTR3B 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.